- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07454148
CART-BP prospektive undersøgelse for hypertensionskontrol
Effekt og sikkerhed af CART BP Pro-vejledt blodtrykshåndtering hos koreanske patienter med ukontrolleret hypertension: Et prospektivt ikke-randomiseret studie
This prospective, open-label, non-randomized study evaluates the effectiveness and safety of a CART BP pro(a brand name of cuffless ambulatory blood pressure monitoring device)-guided blood pressure management strategy in Korean patients with uncontrolled hypertension. Participants are allocated to either a CART BP pro-guided management group or a usual care group based on clinical decision and participant preference. The primary efficacy endpoint is 24-hour mean ambulatory systolic blood pressure at 24 weeks; safety outcomes including treatment-emergent adverse events (TEAEs) are also assessed.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Hypertension remains suboptimally controlled despite combination pharmacotherapy, and office blood pressure measurements may not adequately reflect true ambulatory blood pressure burden and nocturnal patterns. CART BP pro is a wearable, cuffless photoplethysmography-based continuous blood pressure monitoring device. This study investigates whether a CART BP pro-guided antihypertensive titration strategy improves 24-hour ambulatory blood pressure control compared with usual care in real-world outpatient settings. Participants receive standard antihypertensive medications (e.g., angiotensin receptor blocker [ARB], calcium channel blocker [CCB], thiazide diuretic) per guideline-based care. In the CART BP pro-guided group, medication adjustments are informed by CART BP pro-derived 24-hour blood pressure data. The planned follow-up was 24 weeks. Prospective data collection under this non-randomized study protocol has ended. The optional extension to 48 weeks was not undertaken. A separate randomized controlled trial, CARTBP-HTN-P2-2025 (NCT07465549), is ongoing to evaluate CART BP pro-guided blood pressure management under a randomized design. Any future analyses of routinely collected clinical data would be retrospective and subject to applicable institutional review board and consent requirements.
The total actual enrollment was 286 participants. The initial publication (PMID: 42846709) reported a subcohort of 246 participants (67 in the CART BP arm and 179 in the usual-care arm) using data available as of April 6, 2026. Eight participants were lost to follow-up. Of the remaining 238 participants, 162 had valid follow-up ambulatory blood pressure recordings and were included in the primary analysis (38 in the CART BP arm and 124 in the usual-care arm); 76 did not have a valid recording. These publication-specific populations are distinct from the total enrollment of the study.
The registered primary outcome is 24-hour mean ambulatory systolic blood pressure at 24 weeks. The publication described the outcome assessment as the 6-month visit and reported median recording times of 181 days after the index visit in the CART BP arm and 188 days in the usual-care arm. Both arms were scheduled to undergo CART BP pro recording for the outcome assessment. Because ambulatory blood pressure was not systematically measured at baseline, the published primary endpoint was the follow-up blood pressure level, not within-participant change from baseline.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Choose One...
-
Seoul, Choose One..., Sydkorea, 02841
- Korea University Anam Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age >= 19 years
- Office systolic blood pressure(BP) >= 140 mmHg or diastolic BP >= 90 mmHg
- Able and willing to provide written informed consent and comply with follow-up visits
Exclusion Criteria:
- History of intolerance to olmesartan, amlodipine, or hydrochlorothiazide
- Suspected secondary hypertension
- Atrial fibrillation
- Pregnancy or lactation
- Other serious medical condition that may interfere with study participation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: CART BP pro-guided management
Participants undergo 24-hour continuous blood pressure monitoring with CART BP pro. Antihypertensive medications are adjusted based on ambulatory blood pressure data. |
Wearable cuffless continuous blood pressure monitoring device. |
|
Aktiv komparator: Usual care
Participants receive antihypertensive medication adjustments based on office blood pressure measurements according to standard clinical practice. |
Standard hypertension management based on office blood pressure. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
24-hour mean systolic blood pressure
Tidsramme: 24 weeks
|
Between-group difference in 24-hour mean ambulatory systolic blood pressure measured using the CART BP Pro device at 24 weeks. |
24 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAE)
Tidsramme: 24 weeks
|
Proportion of participants experiencing TEAEs during the 24-week study period. |
24 weeks
|
|
24-hour blood pressure load
Tidsramme: 24 weeks
|
Percentage of valid ambulatory BP readings exceeding prespecified thresholds over 24 hours. |
24 weeks
|
|
Office blood pressure change
Tidsramme: 24 weeks
|
Change in office systolic and diastolic blood pressure from baseline to 24 weeks. |
24 weeks
|
|
Target blood pressure achievement rate
Tidsramme: 24 weeks
|
Proportion of participants achieving prespecified ambulatory BP targets. |
24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CARTBP-HTN-P1-2025
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data collected in this study are not currently planned to be shared with external researchers. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .